Skip to content
← Full study record

NCT00720629 · MORE INFO

Limitations, agreements, and source contact

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation · Source last updated 2014-07-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
Study closed early during the first stage, did not proceed to the second stage comparison as planned. Investigators exercised right to close the study prematurely for lack of efficacy, although no protocol-defined end points had been met.
point Of Contact
email
lia.perez@moffitt.org
organization
H. Lee Moffitt Cancer Center and Research Institute
phone
813-745-7202
title
Lia Perez, M.D.
Complete source fields
certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
Study closed early during the first stage, did not proceed to the second stage comparison as planned. Investigators exercised right to close the study prematurely for lack of efficacy, although no protocol-defined end points had been met.
point Of Contact
email
lia.perez@moffitt.org
organization
H. Lee Moffitt Cancer Center and Research Institute
phone
813-745-7202
title
Lia Perez, M.D.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice